W. Marty Blom

Dr. W. Marty Blom

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
BRBenjamin C. Remington
Benjamin C. Remington
JWJoost Westerhout
Joost Westerhout
MMMarie Y. Meima
Marie Y. Meima
WBW. Marty Blom
W. Marty Blom
AKAstrid G. Kruizinga
Astrid G. Kruizinga
JBJoseph L. Baumert
Joseph L. Baumert

1 January 2013 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
WBW. Marty Blom
W. Marty Blom
BVBerber J. Vlieg-Boerstra
Berber J. Vlieg-Boerstra
AKAstrid G. Kruizinga
Astrid G. Kruizinga
SHSicco van der Heide
Sicco van der Heide
GHGeert Houben
Geert Houben
ADAnthony E.J. Dubois
Anthony E.J. Dubois

1 September 2018 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
WBW. Marty Blom
W. Marty Blom
AMAnouska D. Michelsen-Huisman
Anouska D. Michelsen-Huisman
HOHarmieke van Os-Medendorp
Harmieke van Os-Medendorp
GDGert van Duijn
Gert van Duijn
MZMary-Lène de Zeeuw-Brouwer
Mary-Lène de Zeeuw-Brouwer
GHGeert Houben
Geert Houben

24 April 2015 in Allergy
Verified
Journal Article
Closed access
PDF file
BRBenjamin C Remington
Benjamin C Remington
JBJoseph L Baumert
Joseph L Baumert
WBW. Marty Blom
W. Marty Blom
GHGeert Houben
Geert Houben
STSteve L Taylor
Steve L Taylor
AKAstrid G Kruizinga
Astrid G Kruizinga

1 February 2018 in Food and Chemical Toxicology
Verified
Journal Article
Open access
BRB. Remington
B. Remington
HBH.C.H. Broekman
H.C.H. Broekman
WBW. Marty Blom
W. Marty Blom
ACA. Capt
A. Capt
RCR.W.R. Crevel
R.W.R. Crevel
ACA. Constable
A. Constable
The development and introduction of new dietary protein sources has the potential to improve food supply sustainability. Understanding the potential allergenicity of these new or modified proteins is crucial to ensure protection of public health. Exposure to new proteins may result in de novo sensitization, with or without clinical allergy, or clinical reactions through cross-reactivity. In this paper we review the potential of current methodologies (in silico, in vitro degradation, in vitro IgE binding, animal models and clinical studies) to address these outcomes for risk assessment purposes for new proteins, and especially to identify and characterise the risk of sensitization for IgE mediated allergy from oral exposure. Existing tools and tests are capable of assessing potential crossreactivity. However, there are few possibilities to assess the hazard due to de novo sensitization. The only methods available are in vivo models, but many limitations exist to use them for assessing risk. We conclude that there is a need to understand which criteria adequately define allergenicity for risk assessment purposes, and from these criteria develop a more suitable battery of tests to distinguish between proteins of high and low allergenicity, which can then be applied to assess new proteins with unknown risks.

1 November 2019 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
JWJoost Westerhout
Joost Westerhout
JBJoseph L. Baumert
Joseph L. Baumert
WBW. Marty Blom
W. Marty Blom
KAKatrina J. Allen
Katrina J. Allen
BBBarbara Ballmer-Weber
Barbara Ballmer-Weber
BRBenjamin C. Remington
Benjamin C. Remington